cryptocurrency and digital currency, Featured

A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.

A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!The latest progress of stamp duty in Hong Kong has come!The latest news of personal pension fund, incremental funds are coming!

This is a real long-term positive, which is manifested in three aspects: first, it is conducive to attracting investors to invest in the broad-based index through personal pension accounts; Second, it is helpful to inject new long-term funds into the capital market, optimize the investor structure, stabilize the market and promote the healthy development of the capital market; Third, it reflects the care of the regulatory authorities for the capital market and helps to enhance investors' confidence.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".